What is Signatera?

Signatera is a personalized assay created in a lab using tissue from your cancer and optimized to detect circulating tumor DNA (ctDNA) in your blood. Fragments of the cancer’s DNA can be found by running a sample of your blood through the assay which detects  molecular residual disease (MRD), thereby offering broad utility for cancer management. The most common uses are as follows: (1) to monitor for recurrence/MRD after cancer treatment, (2) to help decide whether or not to pursue additional treatment such as chemotherapy, and (3) to help monitor response to ongoing therapies, whether neoadjuvant chemotherapy, immunotherapy, or stage IV cancer treatments.

Signatera is a cancer surveillance test uniquely personalized for each patient. This custom-designed test uses your cancer cells (obtained from the pathology slides) to determine a unique set of tumor mutations that belong to your cancer. A blood sample from you is then taken and analyzed for the presence of any of these mutations. If present (a “positive” result), this information allows you to know earlier that your cancer is likely to recur or has progressed during treatment. These results, positive or negative, can help you have a more informed discussion with your doctor on how to continue to treat your cancer.

What is Altera?

Altera is a test commonly referred to as comprehensive genomic profiling (CGP). Altera tests a number of treatment agents against your tumor, using the tumor block and slides obtained from your cancer. You will receive a personalized report of which agents successfully kill cells from your tumor. Your doctor can then use this information to determine which treatments are best for your cancer. Altera prioritizes potentially beneficial therapies based on your tumor’s biomarkers and cancer type, and provides full details on known cancer driver genes as well as less common biomarkers.

The detailed sequencing report includes FDA-approved treatments, novel treatment approaches and ongoing clinical trials targeting found mutations. FDA-approved treatments for patient-specific genomic targets are provided, as well as novel approaches to detected targets when standard of care is exhausted. In addition, you will receive a list of clinical trials recruiting for detected genomic targets.

Altera can be performed on all invasive solid tumors. Altera cannot be performed on blood cancers at this time.

When should I consider Signatera?

  • All invasive solid tumor types are eligible for testing (stage 0 “in situ” cancers and “blood cancers” such as lymphoma, leukemia, and multiple myeloma are not eligible)
  • One month after surgery, to detect the presence of any residual disease and to guide next steps.
  • During treatment, such as chemotherapy or immunotherapy, to evaluate treatment response at any cancer stage.
  • After treatment, to monitor for early recurrence.

Why is cancer surveillance Important?

Knowing early if there are traces of cancer present in your body can help you and your doctor or oncologist decide:

  • If you are responding to treatment, and if not, which other therapies need to be considered
  • If further cancer treatment needs to be considered
  • If there are signs that the cancer has returned or progressed

I have some questions…

Please be advised that testing cannot be preformed in patients who:

– Have concurrent malignancies (two or more different cancer types that originated in different organs)
– Have a history of allogeneic bone marrow transplant
– Are pregnant
– Have a history of blood transfusions within three months

Let’s Get Started

To order Signatera, please complete the form below. If you don’t have some of the required information handy, you can always save the form and continue it later (your information will be saved for 30 days). Your personal and health information on this firm is always securely encrypted and protected by the latest in cloud-based firewall technology.

Menu